Roche reports 11% sales growth in 1st-qtr 2022

25 April 2022

Swiss pharma giant Roche (ROG: SIX) kicked off the European first-quarter 2022 financial results reporting for the sector today, stating that group sales had increased 11% at constant exchange rates (CER) and 10% in Swiss francs to 16.45 billion francs ($15.75 billion). This was slightly above a market consensus of about 16 billion francs.

Roche does not provide earnings figures at the first-quarter stage, but the firm’s shares were down 2.4% at 388.40 francs by late morning.

Within this Pharmaceutical Division sales were 11.16 billion francs, up 6% at CER, boosted by continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK